Currently there is no targeted treatment for affected individuals with EIF2AK2 mutation.
Management includes early initiation of physical therapy, occupational therapy, and speech therapy. Surveillance includes monitoring growth parameters and assessing for changes in neurological function in the setting of fevers or illnesses.